109 44

Full metadata record

DC FieldValueLanguage
dc.contributor.author최호순-
dc.date.accessioned2019-11-19T05:33:39Z-
dc.date.available2019-11-19T05:33:39Z-
dc.date.issued2017-01-
dc.identifier.citationMEDICINE, v. 96, no. 1, Article no. e5702en_US
dc.identifier.issn0025-7974-
dc.identifier.issn1536-5964-
dc.identifier.urihttps://insights.ovid.com/article/00005792-201701060-00026-
dc.identifier.urihttps://repository.hanyang.ac.kr/handle/20.500.11754/112294-
dc.description.abstractBackground: This phase III trial compared the efficacy and safety of gemcitabine plus capecitabine (GemCap) versus single-agent gemcitabine (Gem) in advanced pancreatic cancer as first-line chemotherapy. Methods: A total of 214 advanced pancreatic cancer patients were enrolled from 16 hospitals in South Korea between 2007 and 2011. Patients were randomly assigned to receive GemCap (oral capecitabine 1660mg/m(2) plus Gem 1000mg/m(2) by 30-minute intravenous infusion weekly for 3 weeks followed by a 1-week break every 4 weeks) or Gem (by 30-minute intravenous infusion weekly for 3 weeks every 4 weeks). Results: Median overall survival (OS) time, the primary end point, was 10.3 and 7.5 months in the GemCap and Gem arms, respectively (P=0.06). Progression-free survival was 6.2 and 5.3 months in the GemCap and Gem arms, respectively (P=0.08). GemCap significantly improved overall response rate compared with Gem alone (43.7% vs 17.6%; P=0.001). Overall frequency of grade 3 or 4 toxicities was similar in each group. Neutropenia was the most frequent grade 3 or 4 toxicity in both groups. Conclusion: GemCap failed to improve OS at a statistically significant level compared to Gem treatment. This study showed a trend toward improved OS compared to Gem alone. GemCap and Gem both exhibited similar safety profiles.en_US
dc.language.isoenen_US
dc.publisherLIPPINCOTT WILLIAMS & WILKINSen_US
dc.subjectcapecitabineen_US
dc.subjectgemcitabineen_US
dc.subjectoverall survivalen_US
dc.subjectpancreatic canceren_US
dc.subjectprogression-free survivalen_US
dc.titleA randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Koreaen_US
dc.typeArticleen_US
dc.relation.no1-
dc.relation.volume96-
dc.identifier.doi10.1097/MD.0000000000005702-
dc.relation.page1-1-
dc.relation.journalMEDICINE-
dc.contributor.googleauthorLee, Hee Seung-
dc.contributor.googleauthorChung, Moon Jae-
dc.contributor.googleauthorPark, Jeong Youp-
dc.contributor.googleauthorBang, Seungmin-
dc.contributor.googleauthorPark, Seung Woo-
dc.contributor.googleauthorKim, Ho Gak-
dc.contributor.googleauthorNoh, Myung Hwan-
dc.contributor.googleauthorLee, Sang Hyub-
dc.contributor.googleauthorKim, Yong-Tae-
dc.contributor.googleauthorChoi, Ho Soon-
dc.relation.code2017001922-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
dc.identifier.pidhschoi96-


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE